These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Role of suppressor cells in cyclosporine-treated allograft recipients. Kerman RH; Flechner SM; Van Buren CT; Lorber MI; Kahan BD Transplant Proc; 1987 Feb; 19(1 Pt 2):1580-3. PubMed ID: 2950632 [No Abstract] [Full Text] [Related]
5. The effect of long-term cyclosporine therapy on natural killer cell activity. Versluis DJ; Metselaar HJ; Bijma AM; Vaessen LM; Wenting GJ; Weimar W Transplant Proc; 1988 Apr; 20(2 Suppl 2):179-85. PubMed ID: 3129839 [No Abstract] [Full Text] [Related]
6. The use of low doses of cyclosporine, azathioprine, and prednisone in renal transplantation. First MR; Alexander JW; Wadhwa N; Penn I; Munda R; Fidler JP; Weiskittel P Transplant Proc; 1986 Apr; 18(2 Suppl 1):132-5. PubMed ID: 3515680 [No Abstract] [Full Text] [Related]
8. Influence of azathioprine and prednisone in vivo treatment on lymphocyte-dependent antibody-mediated cytotoxicity (LDAC) in 57 human renal allograft recipients. Descamps B; Gagnon R; van Der Gaag R; Meyer O; Crosnier J Transplant Proc; 1977 Mar; 9(1):981-4. PubMed ID: 325832 [No Abstract] [Full Text] [Related]
9. [Effect of immunosuppressive therapy on the occurrence of infectious complications]. Mancini C; Lun MT; Lorino G; Gaeta A; D'Erme M; Di Marco P; Capobianchi MR Ann Ist Super Sanita; 1987; 23(4):951-6. PubMed ID: 3132877 [No Abstract] [Full Text] [Related]
10. Sequential conventional immunotherapy with maintenance cyclosporine following renal transplantation. Sommer BG; Henry ML; Ferguson RM Transplant Proc; 1986 Apr; 18(2 Suppl 1):69-75. PubMed ID: 3515698 [No Abstract] [Full Text] [Related]
11. Conversion of immunosuppression in renal allograft recipients from cyclosporine A to azathioprine and prednisolone 6 months after transplantation. Lennard TW; Venning M; Donnelly PK; Wilson RG; Parrott NR; Elliott RW; Proud G; Farndon JR; Ward MK; Wilkinson R Transplant Proc; 1987 Oct; 19(5):3594-6. PubMed ID: 3313866 [No Abstract] [Full Text] [Related]
12. Lipid abnormalities in renal transplant recipients treated with cyclosporine. Vathsala A; Weinberg RB; Schoenberg L; Grevel J; Dunn J; Goldstein RA; Van Buren CT; Lewis RM; Kahan BD Transplant Proc; 1989 Aug; 21(4):3670-3. PubMed ID: 2669278 [No Abstract] [Full Text] [Related]
13. Distinct phenotypic composition of diffuse interstitial and perivascular focal infiltrates in renal allografts: a morphometric analysis of cellular infiltration under conventional immunosuppressive therapy and under cyclosporine A. Guettier C; Nochy D; Hinglais N; Pelletier L; Mandet C; Bedrossian J; Duboust A; Moulonguet Doleris L; Camilleri JP; Bariety J Clin Nephrol; 1988 Aug; 30(2):97-105. PubMed ID: 2972428 [TBL] [Abstract][Full Text] [Related]
14. Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients. Prince HE; Ettenger RB; Dorey FJ; Fine RN; Fahey JL Transplant Proc; 1984 Dec; 16(6):1475-7. PubMed ID: 6390849 [No Abstract] [Full Text] [Related]
15. Conversion of long-term renal allograft recipients from prednisolone/azathioprine to cyclosporine monotherapy. Birkeland SA; Foged N; Kold AA; Svendsen V; Rohr N; Elbirk A Transplant Proc; 1988 Jun; 20(3 Suppl 3):171-5. PubMed ID: 3291237 [No Abstract] [Full Text] [Related]